For example, in recent preclinical research, venetoclax, a BCL-2 inhibitor, enhanced in vitro antibody-dependent cellular phagocytosis of novel anti-CD20 and anti-CD19 antibodies via macrophages in BCL2-expressing double-hit lymphoma [118]. Here, CD19 is linked to lymphoma.